
News|Articles|March 15, 2020
A Case Study in Pharmacopoeia Compliance: Excipients and Raw Materials
Author(s)J. Mark Wiggins, Joseph A. Albanese
This case study is based on the experience of one of the authors but is applicable to all companies across the broader industry, illustrating the potentially surprising point that some compliance difficulties may be of the company’s own making.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Chooses 7 Companies for PreCheck Pilot
2
Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection
3
What to Know About Regulations in June 2026
4
FDA Grants First-in-Class Approval for Treg Cell Therapy in Blood Cancer Transplant Patients
5




